Get the Stockscreener App
0.3526
2.06%
-0.0074
Renovaro Inc stock is traded at $0.3526, with a volume of 390.48K.
It is down -2.06% in the last 24 hours and down -54.08% over the past month.
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
See More
Previous Close:
$0.36
Open:
$0.3567
24h Volume:
390.48K
Relative Volume:
0.33
Market Cap:
$58.22M
Revenue:
-
Net Income/Loss:
$-41.23M
P/E Ratio:
-0.5037
EPS:
-0.7
Net Cash Flow:
$-11.54M
1W Performance:
-2.76%
1M Performance:
-54.08%
6M Performance:
-52.63%
1Y Performance:
-84.12%
1-Day Range:
$0.3408
$0.37
1-Week Range:
$0.3408
$0.42
52-Week Range:
$0.3214
$2.38
Renovaro Inc Stock (RENB) Company Profile
Name
Renovaro Inc
Sector
Industry
Phone
45 39179840
Address
CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES
Compare RENB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RENB
Renovaro Inc
|
0.3526 | 58.22M | 0 | -41.23M | -11.54M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Renovaro Inc Stock (RENB) Latest News
Renovaro Inc (NASDAQ: RENB) Has Great Upside Potential - Stocksregister
Renovaro faces Nasdaq delisting over share price issue - Investing.com Australia
Renovaro faces Nasdaq delisting over share price issue By Investing.com - Investing.com South Africa
Renovaro Inc. (NASDAQ:RENB) Shares Purchased by Corebridge Financial Inc. - Defense World
Renovaro closes merger transaction with BioSymetrics - Pharmaceutical Business review -
Renovaro merges with BioSymetrics to boost AI drug discovery - Investing.com
Renovaro merges with BioSymetrics to boost AI drug discovery By Investing.com - Investing.com South Africa
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven B - GuruFocus
Walmart stands by its annual financial outlook but pulls back its 1Q view amid tariff uncertainty - The Globe and Mail
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine - GlobeNewswire
Major AI Breakthrough: Renovaro-BioSymetrics Merger Creates Powerhouse in Precision Medicine - Stock Titan
Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and ... - Bluefield Daily Telegraph
Morgan Stanley (MS) Is About to Report Q1 Earnings This Week. Here’s What to Expect - The Globe and Mail
CPKC to report first-quarter 2025 earnings results on April 30 - The Globe and Mail
3 Reasons FDP is Risky and 1 Stock to Buy Instead - The Globe and Mail
2 Reasons to Like AMZN and 1 to Stay Skeptical - The Globe and Mail
Predictive Oncology Ends Merger Talks with Renovaro - TipRanks
Renovaro says Predictive Oncology terminates merger transaction - MSN
RENB stock touches 52-week low at $0.4 amid sharp annual decline - Investing.com Canada
Renovaro Biosciences faces merger setback with Predictive Oncology - Investing.com India
Health Care Stocks Tumble On Multiple Fronts - Finimize
Renovaro Says Predictive Oncology Terminates Merger Transaction With Co - marketscreener.com
RENB stock touches 52-week low at $0.4 amid sharp annual decline By Investing.com - Investing.com South Africa
Renovaro Biosciences faces merger setback with Predictive Oncology By Investing.com - Investing.com South Africa
Renovaro BioSciences (RENB) Challenges Merger Termination - GuruFocus
Renovaro Biosciences Announces Breach Of Agreement By Predictive Oncology, Legal Action Pending - Nasdaq
Renovaro Says Predictive Oncology Terminates Merger Deal; Shares Fall - MarketScreener
Renovaro Provides Update to Definitive Agreement with Predictive Oncology - GlobeNewswire
3 Quantum Computing Stocks to Buy Now, According to Analysts – 4/2/2025 - The Globe and Mail
Charles Schwab Investment Management Inc. Buys 163,160 Shares of Renovaro Inc. (NASDAQ:RENB) - Defense World
Predictive Oncology Reports Year-End 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Predictive Oncology pushing forward with Renovaro merger despite $10.8M loss in 2024 - The Business Journals
Predictive Oncology Advances AI Merger Plans Despite $10.8M Loss: Key Strategic Moves Revealed - Stock Titan
Bank of New York Mellon Corp Grows Stake in Renovaro Inc. (NASDAQ:RENB) - Defense World
Recession Risk: Is It Going to Happen? Here Are the Key Clues - The Globe and Mail
3 Reasons TKR is Risky and 1 Stock to Buy Instead - The Globe and Mail
McCormick (MKC) Q1 Earnings: What To Expect - The Globe and Mail
AI Stocks: The Silver Lining in an Otherwise Stormy Tech Market - The Globe and Mail
PawTides.com Partners with Rescue 22 Foundation to Support Veterans and Rescue Dogs - openPR
3 Undervalued Stocks Poised for a Strong Comeback - The Globe and Mail
Rhumbline Advisers Acquires 62,204 Shares of Renovaro Inc. (NASDAQ:RENB) - Defense World
New York State Common Retirement Fund Trims Stake in Renovaro Inc. (NASDAQ:RENB) - Defense World
Ratio Chart Of U.S. Dollar Index Against 10Y U.S. Notes Is Pointing Much Lower - The Globe and Mail
Predictive Oncology receives financing from Renovaro Biosciences - Pennsylvania Business Report -
Renovaro (RENB) and Predictive Oncology Partner for AI-Driven Drug Discovery: What’s Next for Cancer and HIV Treatments? - Yahoo Finance
Sea (SE) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Renovaro provides financing to Predictive Oncology as both move to finalize definitive merger agreement - The Business Journals
MarketsMedicine Hat News - Financial Content
Milestone Merger Payment made with Predictive Oncology to Advance AI-Driven Biomarker Discovery and Precision Medicine in Cancer and Beyond: Renovaro, Inc. (NASDAQ: RENB) - The Globe and Mail
Renovaro Inc Stock (RENB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):